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Abstract: Klebsiella pneumoniae is a clinically relevant pathogen and a frequent cause of
hospital-acquired (HA) and community-acquired (CA) urinary tract infections (UTI). The increased
resistance of this pathogen is leading to limited therapeutic options. To investigate the epidemiology,
virulence, and antibiotic resistance profile of K. pneumoniae in urinary tract infections, we conducted a
multicenter retrospective study for a total of 81 isolates (50 CA-UTI and 31 HA-UTI) in Portugal. The
detection and characterization of resistance and virulence determinants were performed by molecular
methods (PCR, PCR-based replicon typing, and multilocus sequence typing (MLST)). Out of 50
CA-UTI isolates, six (12.0%) carried β-lactamase enzymes, namely blaTEM-156 (n = 2), blaTEM-24 (n = 1),
blaSHV-11 (n = 1), blaSHV-33 (n = 1), and blaCTX-M-15 (n = 1). All HA-UTI were extended-spectrum
β-lactamase (ESBL) producers and had a multidrug resistant profile as compared to the CA-UTI
isolates, which were mainly resistant to ciprofloxacin, levofloxacin, tigecycline, and fosfomycin.
In conclusion, in contrast to community-acquired isolates, there is an overlap between virulence
and multidrug resistance for hospital-acquired UTI K. pneumoniae pathogens. The study is the first
to report different virulence characteristics for hospital and community K. pneumoniae pathogens,
despite the production of β-lactamase and even with the presence of CTX-M-15 ESBL, a successful
international ST15 clone, which were identified in both settings. This highlights that a focus on
genomic surveillance should remain a priority in the hospital environment.
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1. Introduction
The Gram-negative Klebsiella pneumoniae is a clinically relevant pathogen that has the propensity to
acquire multidrug resistance (MDR), thus limiting the therapeutic options for treating related infections
such as pneumonia, liver abscess, meningitis, bloodstream infections, and urinary tract infections
(UTIs) [1].
K. pneumoniae is the second most frequent etiological agent involved in community-acquired (CA)
UTIs [2,3], and it is one of the top three pathogens of international concern documented in the 2017
World Health Organization’s (WHO) Global Priority List of Antibiotic-Resistant Bacteria to Guide
Research, Discovery, and Development of New Antibiotics [4].
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Extended-spectrum β-lactamases (ESBL) are bacterial enzymes that confer resistance against
a number of commonly used classes of β-lactam antibiotics [5]. The emergence of antimicrobial
resistance, as Klebsiella pneumoniae carbapenemases (KPC) and cefotaximases (CTX-M) enzymes
production, additional to the rapid worldwide spread of K. pneumoniae ESBL producers is posing a
serious threat to global health [6], despite the implementation of local and national guidelines [7] as
well as the development innovative approaches that are being considered for therapeutics [8].
K. pneumoniae utilizes a variety of virulence factors, especially capsule polysaccharides, adhesins,
and determinants for iron acquisition, which are used for survival and immune evasion during
infection [9]. Typically, K. pneumoniae is an opportunistic pathogen, which mostly affects those with
weakened immune systems and tends to cause hospital-acquired (HA) infections [10]. However,
virulent K. pneumoniae serotypes can lead to neonatal sepsis in immunocompromised patients [11],
hospital intensive care unit patients [12], or previously healthy persons, and in all cases, it can cause
life-threatening infections [13]. We previously reported a high prevalence of virulence determinants on
multidrug-resistant sequence type (ST)14 KPC-3 carbapenemase K. pneumoniae [14] and detailed the
possibility of this microorganism preceding difficult-to-treat and fatal infections, including those caused
by other Gram-negative pathogens, such as A. baumannii [15]. However, despite the recent interest
in this relationship, the interplay between resistance and virulence in K. pneumoniae clinical isolates
remains poorly understood [9], and to our knowledge, the pathogenic potential of K. pneumoniae in
urinary tract infections, especially in the community setting, and its resistance profile have not yet
been characterized.
Therefore, we conducted a multicenter retrospective study for a total of 81 isolates (50 CA-UTI and
31 HA-UTI) in Portugal with the main goal of investigating the virulence and antibiotic resistance of
K. pneumoniae in urinary tract infections recovered from hospital and community clinic environments.
2. Materials and Methods
2.1. Bacterial Isolates
A total of 81 non-duplicated K. pneumoniae clinical isolates from urinary tract infections were
studied. Only one isolate was considered per patient. The CA-UTI K. pneumoniae isolates (n = 50)
were recovered from 10 community laboratories located in Portugal. Only K. pneumoniae isolates were
selected for the study. The specimens were consecutively collected in the period from January to March
2010. The HA-UTI K. pneumoniae isolates (n = 31) were collected from hospitalized patients at a tertiary
care university hospital center located in Lisbon between 1980 and 2013 and were selected from the
Faculty of Pharmacy, University of Lisboa (FFUL) collection based on the source of isolation (urine
only), by beta-lactamase type, and within this, by random selection. All uropathogens were obtained
as part of routine care and were recovered under standard operating procedures. The identification of
bacteria and β-lactamase production was primarily performed by microbiology laboratories using
conventional methods or automated systems such as Vitek2® (BioMérieux, Marcy, l’Étoile, France)
or MicroScan® (Snap-on, Kenosha, WI, USA). Thereafter, the bacteria were sent to the Faculty of
Pharmacy, Department of Microbiology and Immunology Laboratory for specific molecular studies.
The isolates were frozen in brain heart infusion (BHI) broth (VWR Prolabo, Lisboa, Portugal) with 15%
glycerol at −80 ◦C. Bacterial growth was done using BHI broth (18 h, 37 ◦C) and the bacteria were later
seeded in Luria–Bertani agar (VWR Prolabo®, Lisboa, Portugal).
2.2. Antimicrobial Susceptibility Testing and Phenotypic Detection of Extended-Spectrum β-lactamase
(ESBL) Production
Antimicrobial susceptibility testing was performed using the standardized Kirby–Bauer disk
diffusion technique, in accordance with the European Committee on Antimicrobial Susceptibility
Testing (EUCAST) for Antimicrobial Susceptibility Testing guidelines; the detailed methodology is
available at http://www.eucast.org/ast_of_bacteria/disk_diffusion_methodology/. Detailed instructions
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for Mueller–Hinton agar medium (VWR Prolabo, Lisboa, Portugal), including preparation and storage,
are also available in the same EUCAST guidelines document. Quality control strains were included to
monitor the performance of the test. The K. pneumoniae clinical isolates was tested for their susceptibility
to the following antimicrobial agents: amoxicillin/clavulanic acid (20 µg/10 µg), ceftazidime (10 µg),
cefotaxime (5 µg), cefoxitin (30 µg), ciprofloxacin (5 µg), levofloxacin (5 µg), gentamicin (10 µg),
imipenem (10 µg), meropenem (10 µg), ertapenem (10 µg), tigecycline (15 µg), and fosfomycin
(200 µg). The inhibition zones were interpreted in accordance with EUCAST, except for fosfomycin,
which was interpreted using breakpoints proposed by the Clinical and Laboratory Standard Institute
guidelines [16]. Zone diameters of susceptibility categories were formed according to the proposed
definitions of the 2018 EUCAST Steering Committee [17], which are available at http://www.eucast.org;
namely, categories included (1) susceptible, standard dosing regimen (S); (2) susceptible, increased
exposure (I); (3) and resistant (R). Multidrug resistance (MDR) was defined as non-susceptibility to at
least one agent in three or more antimicrobial categories [18].
The phenotypic double-disk synergy test (DDST), which involves the application of disks
containing ceftazidime next to a disk with amoxicillin–clavulanic acid on Mueller–Hinton agar
plates, was performed on the K. pneumoniae uropathogens that showed resistance to at least one
of the tested third-generation cephalosporins (cefotaxime, ceftazidime). The methodology and
interpretation of results was done according to the EUCAST guidelines for the detection of resistance
mechanisms and specific resistances of clinical and/or epidemiological importance, which are available
at http://www.eucast.org/resistance_mechanisms/.
2.3. Detection of Resistance and Virulence Genes
Isolates were screened by the polymerase chain reaction (PCR) technique using specific primers
for the detection of β-lactamase-associated genes (blaDHA, blaCMY, blaCTX-M, blaSHV), including
carbapenemase genes (blaVIM, blaIMP, blaOXA, and blaKPC). Moreover, the presence of the following
K2 capsule serotypes (K2A) were also investigated; type 1 and type 3 fimbrial adhesins (fimH and
mrkD, namely the subtypes mrkDV1 and mrkDV2-4); siderophore aerobactin (iucC); haemolysin (khe);
regulator of mucoid phenotype A (rmpA); and hypermucoviscosity phenotype (magA) virulence genes.
Among the 79 known capsular serotypes of K. pneumoniae, K1 and K2 have been shown to be the most
prevalent [19] and clinically relevant, despite their association with invasive infections [20–22]. The
search for only the K2 capsular type was justified considering that K1 is mainly related to hypervirulent
K. pneumoniae variants (hvKP), which cause pyogenic liver abscesses and other infections [23] and
are mainly found in Asian countries [21], while K2 is usually related to non-hvKP isolates, which
cause severe and difficult-to-treat infections [21,24,25]. Additionally, hypervirulent K. pneumoniae
isolates are defined by either capsular type K1 or K2 (which confers different virulence characteristics
such as serum resistance) or the presence of one of the following virulence genes: aerobactin (iuc),
rmpA/rmpA2, and/or salmochelin (iro) [23].
The PCR methodology, including primer sequences, lengths of expected PCR products, quality
control strains, as well the purification technique and nucleotide sequences analysis were previously
described in detail [14].
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2.4. Multilocus Sequence Typing
A total of twenty-four isolates, namely the eleven KPC-3 carbapenemase producers and thirteen
CTX-M-15 cefotaximase extended-spectrum beta-lactamase-producing K. pneumoniae isolates (12
HA-UTI and 1 CA-UTI) were selected for multilocus sequence typing (MLST) after sequencing
(Macrogen, Inc., Korea). Primers, PCR reaction conditions, and detailed methodology were in
accordance with those previously described by Diancourt, L. et al. [26]. The allele attribution and
sequence type (ST) identification was done with the K. pneumoniae MLST database platform from
Institute Pasteur (http://www.pasteur.fr/mlst/; Last accessed on 2 May 2018).
2.5. PCR-based Replicon Typing
The molecular identification and classification of plasmids, namely the identification of origins of
plasmid replicates belonging to different incompatibility groups, was performed by the PCR-based
replicon typing (PBRT) technique described by Carattoli, A. et al. [27].
2.6. Statistical Analysis
The statistical analysis used the Fisher’s exact test, using the computer program available at
http://www.graphpad.com/quickcalcs/index. A probability value of p ≤ 0.05 was considered to indicate
statistical significance.
2.7. Ethical Approval
The Ethics Committee of the Faculty of Medicine, Universidade de Lisboa approved this study
proposal. All isolates were recovered as part of routine testing, studied anonymously, and the
epidemiological data were obtained retrospectively from clinical records.
3. Results
3.1. Antimicrobial Susceptibility
The susceptibility of the CA-UTI K. pneumoniae isolates was found to be 100% (50/50) to meropenem
and ertapenem, 98% (49/50) to gentamicin, 94% (47/50) to ceftazidime, cefoxitin, and cefotaxime, 88%
(44/50) to amoxicillin/clavulanic acid and levofloxacin, 86% (43/50) to imipenem, and 84% (42/50)
to ciprofloxacin. Higher resistance rates were found for ciprofloxacin, levofloxacin, tigeciclin, and
fosfomycin with 10% (5/50) resistant isolates for each. Fourteen percent (7/50), 28% (14/50), and
38% (19/50) of the isolates belonged to category I (susceptible, increased exposure) for imipenem,
fosfomycin, and tigeciclin, respectively. The results are shown in Figure 1. On the other hand,
the HA-UTI K. pneumoniae isolates showed a full antimicrobial resistance profile, namely, 93.5%
(29/31), 87.1% (27/31), and 64.5% (20/31) of the isolates were resistant to ceftazidime, cefotaxime, and
amoxicilin/clavulanic acid, respectively. Additionally, 83.9% (26/31) and 41.9% (13/31) of the isolates
were resistant to gentamicin and ciprofloxacin, respectively. The most active antibiotics were shown to
be fosfomycin (93.5%, 20/31), imipenem (74.2%, 23/31), and meropenem, and ertapenem (64.5%, 20/31
each). Imipenem and fosfomycin were found to be non-susceptible, increased exposure (I) isolates.
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Figure 1. Antimicrobial susceptibilities of the K. pneumoniae clinical isolates (n = 81). The isolates were 
recovered from community-acquired (CA)-urinary tract infection (UTI) and hospital-acquired 
(HA)-UTI patients. The CA isolates were consecutively collected while the HA isolates were selected 
from the FFUL collection based on the source of isolation (urine only), beta-lactamase type produced, 
and within this, by random selection. Legend: AMC, amoxicillin/clavulanic acid; FOX, cefoxitin; CAZ, 
ceftazidime; CTX, cefotaxime; CIP, ciprofloxacin; LVF, levofloxacin, GM, gentamicin; IMP, imipenem; MER, 
meropenem; ERT, ertapenem; TIG, tigecycline; FOS, fosfomycin; FFUL, Faculty of Pharmacy University of Lisboa. 
3.2. Identification of the β-Lactamases 
PCR amplification of β-lactamase genes was performed in CA-UTI and HA-UTI K. pneumoniae 
isolates. ESBL production was detected in six (12.0%) CA-UTI K. pneumoniae isolates, namely, 
blaTEM-156 (n = 2), blaTEM-24 (n = 1), blaSHV-11 (n = 1), blaSHV-33 (n = 1), and blaCTX-M-15 (n = 1). The results are 
presented in Table 1. The multidrug resistant HA-UTI K. pneumoniae isolates carried the ESBLs 
blaTEM-10 (19.3%, 6/31), blaTEM-24 (9.6%, 3/31), blaCTX-M-15 (38.7%, 12/31), blaKPC-3 (19.3%, 6/31), blaKPC-3 and 
blaSHV-11 (3.2%, 1/31), and blaKPC-3 and blaCTX-M-15 (12.9%, 4/31). The genes blaDHA, blaCMY, blaIMP, blaVIM, 
blaNDM, and blaOXA were not detected in our study. The replicon typing plasmids found are also 
presented in Table 1. The conjugative plasmid IncFIA was the most commonly found (66.7%, 4/6) 
CA-UTI K. pneumoniae β-lactamase producer, while HI1 (CTX-M-15 producers), A/C, and F (KPC-3 
producers) were mainly present (38.7% 12/31, 22.6% 7/31, and 25.8% 8/31, respectively) on the 
HA-UTI K. pneumoniae isolates The plasmids were non-typeable by the former scheme among eight 
isolates. 
3.3. Virulence Genes 
Of all the K. pneumoniae UTI clinical isolates (n = 81), whose results are shown in Table 2, the 
major virulence genes identified were fimH (63%, 51/81), mrkDV1 (49.3%, 40/81), and khe (60.5%, 
49/81). A total of 38.2% (31/81) of the isolates showed the presence of mrkDV2-4, while 18.5% (15/81) 
and 16.0% (13/81) showed the iucC and K2A genes, respectively. No magA and rmpA genes were 
amplified. The type 3 fimbrial adhesin mrkDV1 was predominant in HA-UTIs (96.8%, 30/31) but not 
in CA-UTIs (20.0%, 10/50), while mrkDV2-4 was the most common type 3 fimbrial adhesin (62.0%, 
31/50 vs. 20.0% 10/50) in CA-UTIs, and it was only found in these isolates. Additionally, higher 
virulence potential was found in the HA-UTI isolates with an average of 3.29 virulence factors per 
isolate in HA-UTI vs. 1.94 virulence factors per isolate in CA-UTI.  
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3.2. Identification of the β-Lactamases
PCR amplification of β-lactamase genes was performed in CA-UTI and HA-UTI K. pneumoniae
isolates. ESBL production was detected in six (12.0%) CA-UTI K. pneumoniae isolates, namely, blaTEM-156
(n = 2), blaTEM-24 (n = 1), blaSHV-11 (n = 1), blaSHV-33 (n = 1), and blaCTX-M-15 (n = 1). The results
are presented in Table 1. The multidrug resistant HA-UTI K. pneumoniae isolates carried the ESBLs
blaTEM-10 (19.3%, 6/31), blaTEM-24 (9.6%, 3/31), blaCTX-M-15 (38.7%, 12/31), blaKPC-3 (19.3%, 6/31), blaKPC-3
and blaSHV-11 (3.2%, 1/31), and blaKPC-3 and blaCTX-M-15 (12.9%, 4/31). The genes blaDHA, blaCMY, blaIMP,
blaVIM, blaNDM, and blaOXA were not detected in our study. The replicon typing plasmids found are
also presented in Table 1. The conjugative plasmid IncFIA was the most commonly found (66.7%, 4/6)
CA-UTI K. pneumoniae β-lactamase producer, while HI1 (CTX-M-15 producers), A/C, and F (KPC-3
producers) were mainly present (38.7% 12/31, 22.6% 7/31, and 25.8% 8/31, respectively) on the HA-UTI
K. pneumoniae isolates The plasmids were non-typeable by the former scheme among eight isolates.
3.3. Virulence Genes
Of all the K. pneumoniae UTI clinical isolates (n = 81), whose results are shown in Table 2, the major
virulence genes identified were fimH (63%, 51/81), mrkDV1 (49.3%, 40/81), and khe (60.5%, 49/81). A total
of 38.2% (31/81) of the isolates showed the presence of mrkDV2-4, while 18.5% (15/81) and 16.0% (13/81)
showed the iucC and K2A genes, respectively. No magA and rmpA genes were amplified. The type
3 fimbrial adhesin mrkDV1 was predominant in HA-UTIs (96.8%, 30/31) but not in CA-UTIs (20.0%,
10/50), while mrkDV2-4 was the most common type 3 fimbrial adhesin (62.0%, 31/50 vs. 20.0% 10/50) in
CA-UTIs, and it was only found in these isolates. Additionally, higher virulence potential was found in
the HA-UTI isolates with an average of 3.29 virulence factors per isolate in HA-UTI vs. 1.94 virulence
factors per isolate in CA-UTI.
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Table 1. Antibiotic resistance profile, distribution of virulence genes, and plasmid content of β-lactamases-producing K. pneumoniae community-acquired UTI isolates.
Isolate ID Date of Isolation β-Lactamase Produced Antibiotics Resistance Profile Virulence Profile PBRT MLST
CA-UTI isolates
201-010 2010 TEM-156 CIP, LVF khe, mrkDV1 FIA NP
201-075 2010 SHV-11 CIP, FOS mrkDV2-4 FIA, X, Y NP
201-076 2010 TEM-24 LVF, FOS No VG X, A/C NP
201-094 2010 TEM-156 AMC, FOS mrkDV1 W NP
208-309 2010 SHV-33 NR fimH, mrkDV2-4, iucC FIA, Y NP
212-193 2010 CTX-M-15 AMC, CAZ, CTX, CIP, LVF khe, iucC FIA, HI2 ST15
HA-UTI isolates
625 1980 TEM-10 GM K2, fimH, khe, mrkDV1 NT NP
683 1999 TEM-10 AMC, CTX, CAZ, GM K2, fimH, khe, mrkDV1 NT NP
684 1999 TEM-10 AMC, CAZ, GM K2, fimH, khe, mrkDV1 NT NP
712 1999 TEM-24 AMC, CTX, CAZ fimH, khe, mrkDV1 NT NP
721 1999 TEM-10 AMC, CTX, CAZ, GM fimH, khe, mrkDV1 NT NP
732 2000 TEM-10 AMC, CTX, CAZ, GM fimH, khe, mrkDV1 NT NP
749 2001 TEM-24 AMC, FOX, CTX, CAZ, CIP fimH, khe NT NP
770 2001 TEM-24 AMC, FOX, CTX, CAZ, CIP fimH, khe NT NP
775 2001 TEM-10, CTX-M-15 CAZ, GM fimH, khe, mrkDV1 HI1 ST15
847 2003 CTX-M-15 AMC, CTX, CAZ, GM, CIP fimH, khe, mrkDV1 HI1 ST15
931 2004 CTX-M-15 CTX, CAZ, GM, CIP fimH, khe, mrkDV1 HI1 ST15
1119 2005 CTX-M-15 CTX, CAZ, GM, CIP fimH, khe, mrkDV1 HI1 ST15
1263 2007 CTX-M-15 GM, CIP fimH, khe, mrkDV1 HI1 ST15
2323 2008 CTX-M-15 AMC, CTX, CAZ, GM fimH, khe, mrkDV1 HI1 ST15
2325 2008 CTX-M-15 AMC, CTX, CAZ, GM fimH, mrkDV1 HI1 ST15
2386 2008 CTX-M-15 CTX, CAZ, GM fimH, khe, mrkDV1 HI1 ST15
2394 2008 CTX-M-15 CTX, CAZ, GM fimH, khe, mrkDV1 HI1 ST15
2398 2008 CTX-M-15 CTX, CAZ, GM, CIP fimH, mrkDV1 HI1 ST15
2400 2008 CTX-M-15 CTX, CAZ, GM fimH, khe, mrkDV1 HI1 ST15
2414 2008 CTX-M-15 CTX, CAZ, GM, CIP fimH, khe, mrkDV1 HI1 ST15
2909 2009 KPC-3, SHV-11 AMC, CTX, CAZ, IMP, GM, MEM,ERT K2, fimH, khe, mrkDV1 F ST14
2954 2010 KPC-3 AMC, FOX CTX, CAZ, IMP, GM, LVF,TIG, MEM, ERT K2, fimH, khe, mrkDV1 A/C, F ST14
3108 2010 KPC-3 AMC, CTX, CAZ, TIG, MEM, ERT khe, mrkDV1, iucC FIA, F ST14
29078 2010 KPC-3, CTX-M-15 AMC, FOX, CTX, CAZ, IMP, GM,MEM, ERT, FOS fimH, khe, mrkDV1,iucC FIA, F ST14
43201 2010 KPC-3, CTX-M-15 AMC, FOX, CTX, CAZ, IMP, GM, CIP,LVF, MEM, ERT
K2, fimH, khe,
mrkDV1,iucC
A/C ST14
61095 2011 KPC-3, CTX-M-15 AMC, CTX, CAZ, IMP, GM, CIP, LVF,MEM, ERT, TIG K2, fimH, mrkDV1 A/C, F ST14
72562 2011 KPC-3 AMC, FOX, CTX, CAZ, MEM, ERT fimH, mrkDV1,iucC A/C ST14
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Table 1. Cont.
Isolate ID Date of Isolation β-Lactamase Produced Antibiotics Resistance Profile Virulence Profile PBRT MLST
87582 2012 KPC-3 AMC, FOX, CTX, CAZ, IMP, GM, CIP,LVF, MEM, ERT, FOS fimH, khe, mrkDV1,iucC F ST14
91488 2012 KPC-3, CTX-M-15 CTX, CAZ, GM, CIP, LVF, MEM, ERT K2, fimH, khe, mrkDV1 A/C, F ST14
22073 2013 KPC-3 AMC, FOX, CTX, CAZ, IMP, GM, CIP,LVF, MEM, ERT K2, fimH, khe, mrkDV1 A/C ST14
31149 2013 KPC-3 AMC, CTX, CAZ, IMP, GM, MEM,ERT K2, fimH, mrkDV1,iucC A/C, F ST14
Legend: CA-UTI, community-acquired urinary tract infection; HA-UTI, hospital-acquired urinary tract infection; ID, identification; Nr., number; No VG; no virulence genes found; NR, no
resistance found; CIP, ciprofloxacin; LVF, levofloxacin; AMC, amoxicillin/clavulanic acid; FOS, fosfomycin; CAZ, ceftazidime; CTX, cefotaxime; FOX, cefoxitin; GM, gentamicin; IMP,
imipenem; MER, meropenem; ERT, ertapenem; TIG, tigecycline; PBRT, PCR-based replicon typing; NT, non-typeable; NP, not performed; MLST, multilocus sequence typing; ST, sequence
type; KPC, Klebsiella pneumoniae carbapenemase; CTX, cefotaximase.
Table 2. Distribution of virulence genes in K. pneumoniae isolates from community-acquired urinary tract infections (CA-UTI) and hospital-acquired urinary tract
infections (HA-UTI).
Virulence Factor Target Gene
Nr. of CA-UTI Isolates (%) Nr. of HA-UTI Isolates (%) Total (%)
(n = 50) (n = 31) (n = 81)
Fimbrial adhesins
Type 1 fimH 20 (40.0) 31 (100.0) * 51 (63.0)
Type 3, variant 1 mrkDV1 10 (20.0) 30 (96.8) * 40 (49.3)
Type 3, variant 2-4 mrkDV2-4 31 (62.0) 0 * 31 (38.2)
Toxin Haemolysin khe 23 (46.0) 26 (83.9) * 49 (60.5)
Capsular type K2 serotype K2A 3 (6.0) 10 (32.2) * 13 (16.0)
Siderophore Aerobactin iucC 10 (20.0) 5 (16.1) 15 (18.5)
Protectins or invasins
Mucoviscosity phenotype magA 0 0 0
Regulator of mucoid phenotype rmpA 0 0 0
Legend: CA-UTI, community-acquired urinary tract infection; HA-UTI, hospital-acquired urinary tract infection; Nr., number; * p-values less than 0.05 were considered statistically significant.
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In order to identify how the virulence genes were simultaneously present on the same isolate, we
characterized the virulence profiles (VP) of both CA- and HA-UTI K. pneumoniae uropathogens. The
results are presented in Table 3.
Table 3. Characterization of virulence profiles of community- and hospital-acquired UTI K.
pneumoniae isolates.
Nr. of Virulence
Genes
Virulence
Profile (VP) Virulence Genes
Nr. Isolates (%)
CA-UTI
n = 50 (100)
HA-UTI
n = 31 (100)
Total
n = 81 (100)
0 VF 1 No VF 8 (16.0) 0 8 (9.9)
1 VF 2 khe 5 (10.0) 0 5 (6.2)
3 fimH 1 (2.0) 0 1 (1.2)
4 mrkDV1 2 (4.0) 0 2 (2.5)
5 mrkDV2-4 3 (6.0) 0 3 (3.7)
2 VF 6 fimH, khe 2 (4.0) 2 (6.3) 4 (4.9)
7 fimH, mrkDV1 0 3 (9.4) 3 (3.7)
8 khe, iucC 1 (2.0) 0 1 (1.2)
9 iucC, mrkDV2-4 2 (4.0) 0 2 (2.5)
10 khe, mrkDV1 2 (4.0) 0 2 (2.5)
11 khe, mrkDV2-4 5 (10.0) 0 5 (6.2)
12 fimH, mrkDV2-4 5 (10.0) 0 5 (6.2)
13 fimH, khe, mrkDV1 2 (4.0) 13 (40.6) 15 (18.5)
14 fimH, khe, iucC 1 (2.0) 0 1 (1.2)
15 fimH, khe, mrkDV2-4 2 (4.0) 0 2 (2.5)
3 VF 16 fimH, iucC, mrkDV1 2 (4.0) 1 (3.1) 3 (3.7)
17 fimH, iucC, mrkDV2-4 4 (8.0) 0 4 (4.9)
18 khe, mrkDV1, iucC 0 1 (3.1) 1 (1.2)
19 K2, khe, mrkDV1 2 (4.0) 0 2 (2.5)
20 K2, fimH, mrkDV1 0 1 (3.1) 1 (1.2)
21 K2, fimH, khe, mrkDV2-4 1 (2.0) 0 1 (1.2)
4 VF 22 K2, fimH, khe, mrkDV1 0 7 (21.9) 7 (8.6)
23 fimH, khe, mrkDV1, iucC 0 2 (6.3) 2 (2.5)
5 VF 24 K2, fimH, khe, mrkDV1,iucC 0 1 (3.1) 1 (1.2)
Legend: VF, virulence factor; VP, virulence profile; CA-UTI, community-acquired urinary tract infection; HA-UTI,
hospital-acquired urinary tract infection.
A total of 24 different virulence profiles was identified in our study (Table 3). The most frequent
virulence profile found was VP13 (fimH, khe, mrkDV1), which was observed in 18.5% (15/81) of the
isolates, but mainly in HA-UTI isolates (40.6% HA-UTI vs. 4.0% CA-UTI, p < 0.05). A similar finding
was obtained for VP22 (K2, fimH, khe, mrkDV1) which showed a prevalence of 8.6% (7/81) but was only
found in HA-UTI isolates (21.9%, 7/31). Similarly, virulence profiles with no virulence genes (9.9%,
8/81) and one virulence factor, namely VP2 with the virulence factor khe, accounted for 6.2% (5/81) of
the isolates, and this type of profile was only found in CA-UTI K. pneumoniae isolates. All HA-UTI
isolates harbored at least one virulence gene. Moreover, the HA-UTIs presented only nine virulence
profiles (VP 13 and VP 22 with two and four virulence genes, respectively, accounted for 62.5% of the
isolates) while CA-UTI virulence profiles were distributed among 18 virulence profiles, and the most
frequent profiles, VP 1 and VP2, presented 0 and 1 virulence factors, respectively, and accounted for
only 26.0% of the CA-UTI isolates.
3.4. MLST Results
The clonal relatedness of the MDR CTX-M-15 ESBL K. pneumoniae producers, including one
isolate identified in the community setting, was investigated by multilocus sequence typing (MLST).
CTX-M-15 was included due to its clinical relevance to human health and because it is the only
extended-spectrum-β-lactamase shared between hospital and community settings. The ST15 clone
was identified in all CTX-M-15 isolates studied (100.0%, 13/13).
Microorganisms 2019, 7, 138 9 of 14
4. Discussion
Multidrug resistance and virulence are typically observed in separate K. pneumoniae
populations [28] and their interplay remains poorly understood [9]. Recent reports have shown
that K. pneumoniae strains can accumulate, increasing their pathogenicity and causing severe and
difficult-to-treat infections. However, the available reports mainly cover the hypervirulent phenotypes
of K. pneumoniae (mainly related to pyogenic liver abscesses and meningitis [28,29]), focus on
carbapenemase producers [30], and were performed in the hospital setting [14,25]. Our study
characterizes the virulence and antibiotic resistance traits of K. pneumoniae in urinary tract infections
recovered from both community and hospital settings. Additionally, this is the first report of a
community-acquired urinary tract infection related to the CTX-M-15 ESBL K. pneumoniae producer,
which belongs to the successful international ST15 clone, in Portugal.
The majority of CA-UTI K. pneumoniae pathogens characterized in our study were susceptible
isolates; the antimicrobial susceptibility was >80% in eight out of ten tested antibiotics. However, the
number of isolates belonging to category I (susceptible, increased exposure) found for imipenem (14%)
deserves particular attention considering that the isolates were inhibited in vitro by a concentration
of antibiotics that is associated with an uncertain therapeutic effect. In Portugal, carbapenems
consumption is increasing [31]. Portugal is now one of the top consumers in Europe, and resistance
to antibiotics of this class has changed from 5.2% in 2016 [32] to 8.6% in 2017 [33] according to the
resistance surveillance network (EARS-Net) of the European Centre for Disease Prevention and Control
(ECDC). Strict monitoring of imipenem consumption and continuous monitoring of evolutionary trends
in the susceptibility patterns of K. pneumoniae, especially regarding community-acquired infections,
is mandatory.
Limited data are available on the susceptibility to recently accessible antimicrobial agents, such
as tigecycline, along with some “older” antibiotics, such as fosfomycin, particularly on multidrug
and ESBL-producing Gram-negative microorganisms [34]. The in vitro activities of these antibiotics
were determined against K. pneumoniae isolates recovered from community- and hospital-acquired
urinary tract infections. Surprisingly, a significantly lower susceptibility (62% CA-UTI vs. 94% MDR
HA-UTI) to the fosfomycin antibiotic was found for CA-UTI K. pneumoniae isolates when compared
with HA-UTIs. Similarly, susceptibility rates of 96% for MDR Enterobacteriaceae [35] and 89% for K.
pneumoniae KPC producers were found [14], including a report showing that extremely drug-resistant
K. pneumoniae KPC producers, including tigecycline and colistin resistant types, were susceptible to
fosfomycin [36]. However, lower fosfomycin activity has been previously reported, perhaps due to
differences in local epidemiology [29]. The present study demonstrates that fosfomycin, an older
antimicrobial agent, should be considered to be an emerging treatment option for difficult-to-treat
hospital-acquired urinary tract infections caused by K. pneumoniae uropathogens, including MDR
isolate multidrugs, but caution should be applied for its use as an alternative agent for outpatient
therapy of UTIs.
The presence of virulence factors has an important contribution to the pathogenesis of
K. pneumoniae [13] and to the development of severe and invasive forms of infection, not only
in immunocompromised individuals but also in previously healthy adults [11,25,37]. Bandeira et al.
support the hypothesis that biofilms formed on medical devices can promote the onset and spread of
healthcare-associated infections, and they reported that biofilm-forming bacteria are generally more
resistant to antibiotics [37]. In our study, the most frequent virulence factors found were fimH and
the mrkD, which encode type 1 and type 3 fimbrial adhesins, respectively, which mediate binding
to epithelial cells of the urinary tract and promote biofilm development [38–40]. In fact, despite the
findings of the present study being similar to those of other studies that have reported the ubiquitous
nature of these fimbriae in K. pneumoniae [40,41], a significantly higher prevalence of fimbriae on
HA uropathogens when compared with CA isolates was found in our study. This could lead to the
infection of medical devices and may explain their persistence and difficulty of eradication in the
hospital setting.
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The genes involved in the synthesis of siderophores have dual roles as they can also inhibit T
cell proliferation, promoting host immunosuppression, in addition to their role in enhancing iron
uptake [42]. The iron siderophore aerobactin synthase gene (iucC) was detected in 19% of the isolates
and showed similar prevalence between CA and HA uropathogens. Despite the prevalence found in
our study being lower than that previously reported (32%) [25], it is unusual to have high identification
of community-provenance isolates. The rmpA and magA genes were not found in our uropathogens.
These genes are frequently identified in K. pneumoniae causing liver abscesses, particularly in Asian
countries [43,44]. The capsule polysaccharide K2 serotype has been previously reported as a major
contributor to the virulence of K. pneumoniae isolates [45]. It confers resistance to phagocytosis [46] and
is related to severe infections [47]. In our study, 16.0% (13/81) of the isolates showed the K2 capsular
serotype, mainly MDR HA uropathogens. Despite the results being in accordance with previous
reports [45], unusual capsular types have been described in carbapenem-resistant K. pneumoniae strains,
such as K64 and K62. [48]. Therefore, future studies on virulence should consider the characterization
of capsular types for Klebsiella spp. strains [47].
Differences between uropathogens from the hospital and community settings were also found in
terms of the accumulation of virulence genes by each isolate. The K. pneumoniae recovered from the
hospital setting showed higher pathogenic potential, with higher genomic complexity and adaptation
to two specific profiles. These findings have important clinical relevance, considering that the presence
of virulence factors in K. pneumoniae has been previously described as the most prominent cause
of death in patients before starting antibiotic therapy [49]. The virulence profiles VP13 (fimH, khe,
mrkDV1) and VP22 (K2, fimH, khe, mrkDV1) were predominant in the hospital-acquired collection. The
accumulation of type 1 and type 3 fimbrial adhesins with haemolysin, a toxin that has cytolytic and
cytotoxic activity against a wide range of mammalian cell types [50], seems to be an effective virulence
combination. Additionally, it is notable that both major virulence profiles identified in HA-UTIs had
the same virulence genes, with or without the presence of capsular serotype K2.
High diversity and low accumulation of virulence genes in the same isolate was identified in
K. pneumoniae community uropathogens, reinforcing the low pathogenicity of these isolates reported in
our study.
A proficient pathogen should be virulent, resistant to antibiotics, and epidemic [9]. Genotyping of
the multidrug-resistant CTX-M-15-producing K. pneumoniae isolates by MLST recovered the ST15 clone
in isolates from both hospital and community settings. Of relevance, no associations between the ST15
MLST type, antimicrobial resistance, and virulence profiles, or between the ESBLs produced and the
virulence profiles, were found in our study. However, there was a clear accumulation of virulence
factors in highly multidrug resistant K. pneumoniae clinical isolates recovered from hospital-acquired
urinary tract infections when compared with those recovered from the community setting, which
showed low resistance and a low virulent potential profile. These results indicate a direct relationship
and relevant clinical interplay between resistance and virulence in K. pneumoniae clinical isolates, and
the supremacy of antimicrobial resistance appears to be the leading factor.
In 2018, we reported that the ST11 that belongs to the CC258 group, one of the most threating
MDR Gram-negative bacterias circulating in nosocomial settings worldwide [51], has been replaced
by the ST14 clone KPC-3 carbapenemase-producing K. pneumoniae isolates [14]. In the present study
we report the identification of the ST15 clone of CTX-M-15-producing K. pneumoniae in both the
hospital and community settings and demonstrate that this clone can accumulate virulence and MDR.
ST15 is described as a successful international clone that is present worldwide and has recently been
associated with colistin-resistant infections [52]. It is highly virulent and resistant [53] and was one of
the first K. pneumoniae isolates in the United States to be reported to the Centers for Disease Control
and Prevention (CDC) as non-susceptible to all drugs tested, including all beta-lactams, colistin, and
tigecycline [54]. A limitation of the present study is that we showed only a small part of the real
epidemiological situation considering the collection studied. Also, despite being a multicenter study,
not all districts of Portugal were included, and the period of study can be considered too large for a short
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number of isolates. Additionally, only CTX-M-15 and KPC-3 producers were characterized by MLST.
Future studies should expand the collection of pathogens tested and the number of centers involved in
order to provide a more complete picture of the dissemination of K. pneumoniae in Portugal. However, a
complete microbiological and molecular characterization of K. pneumoniae strains collected from urinary
tract infections was performed, including antimicrobial resistance profiling, ESBL characterization,
and detection of virulence determinants. Thus, the results found in this study have great importance
from both the clinical and research points of view.
5. Conclusions
In conclusion, there is an overlap between virulence and multidrug resistance in MDR
hospital-acquired UTI K. pneumoniae pathogens but not in community-acquired isolates. Different
virulence characteristics were reported, despite the production of β-lactamase and even in the presence
of the successful international CTX-M-15 ESBL ST15 clone in both settings. These results highlight that
the genomic surveillance focus should remain a priority in the hospital environment.
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